← Back to Screener
Estrella Immunopharma, Inc. Common Stock (ESLA)
Price$1.81
Favorite Metrics
Price vs S&P 500 (26W)36.99%
Price vs S&P 500 (4W)71.28%
Market Capitalization$80.21M
All Metrics
Book Value / Share (Quarterly)$0.00
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.05
Price vs S&P 500 (YTD)16.37%
EPS (TTM)$-0.36
10-Day Avg Trading Volume0.30M
EPS Excl Extra (TTM)$-0.36
EPS (Annual)$-0.35
ROI (Annual)-3080.10%
Cash / Share (Quarterly)$0.04
ROA (Last FY)-411.19%
EBITD / Share (TTM)$-0.35
ROE (5Y Avg)-661.69%
Cash Flow / Share (Annual)$-0.05
P/B Ratio558.06x
P/B Ratio (Quarterly)302.06x
ROA (TTM)-430.95%
EPS Incl Extra (Annual)$-0.35
Current Ratio (Annual)0.12x
Quick Ratio (Quarterly)0.10x
3-Month Avg Trading Volume0.17M
52-Week Price Return124.77%
52-Week High$3.15
EPS Excl Extra (Annual)$-0.35
26-Week Price Return45.74%
Quick Ratio (Annual)0.10x
13-Week Price Return80.77%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.12x
Enterprise Value$78.826
Cash / Share (Annual)$0.04
3-Month Return Std Dev119.86%
ROE (Last FY)-3080.10%
EPS Basic Excl Extra (Annual)$-0.35
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.36
ROI (TTM)-259.11%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)89.68%
Year-to-Date Return20.51%
5-Day Price Return7.43%
EPS Normalized (Annual)$-0.35
ROA (5Y Avg)-218.72%
Month-to-Date Return77.36%
EBITD / Share (Annual)$-0.35
ROI (5Y Avg)-661.69%
EPS Basic Excl Extra (TTM)$-0.36
P/B Ratio (Annual)302.06x
Book Value / Share (Annual)$0.00
Price vs S&P 500 (13W)77.90%
Beta1.13x
Revenue / Share (TTM)$0.00
ROE (TTM)-259.11%
52-Week Low$0.78
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ESLAEstrella Immunopharma, Inc. Common Stock | — | — | — | — | $1.81 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing ARTEMIS T-cell therapies targeting CD19 and CD22 antigens for blood cancers and solid tumors. The company's engineered cell therapy approach addresses current treatment limitations in oncology and autoimmune diseases.